My understanding of a double blinded trial is that the researchers have access to the same data at the same time as in an open label study (of course without knowledge of who received the sham surgery). The researchers will conduct their assessment in the same way as in an open label study and sign off on their findings prior to unbinding. All the analysis and assessment will be completed prior to unbinding, where following the unbinding the researchers are then able to review (but not amend) their findings.
If this is correct we could expect release of top line results by mid November, as all analysis will be complete by the end of October.
- Forums
- ASX - By Stock
- 1AI
- channel 7 parkinson
channel 7 parkinson, page-10
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1AI (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.81M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
22 | 6044404 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 1428165 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
22 | 6044404 | 0.006 |
11 | 4577719 | 0.005 |
6 | 3695009 | 0.004 |
2 | 3100000 | 0.003 |
2 | 1050000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 1428165 | 3 |
0.008 | 2252112 | 10 |
0.009 | 2028673 | 10 |
0.010 | 2788587 | 5 |
0.011 | 208125 | 2 |
Last trade - 16.12pm 14/10/2024 (20 minute delay) ? |
Featured News
1AI (ASX) Chart |
Day chart unavailable
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, Managing Director & CEO
Charles Armstrong
Managing Director & CEO
SPONSORED BY The Market Online